Skip to content

    Recently Viewed

      Listening...

      Johnson & Johnson Reports 2015 Third-Quarter Results:

      Sales of $17.1 Billion Decreased 7.4% Versus 2014 Third Quarter

      Share Article
      share to

      NEW BRUNSWICK, N.J., Oct. 13, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.1 billion for the third quarter of 2015, a decrease of 7.4% as compared to the third quarter of 2014. Operational sales results increased 0.8% and the negative impact of currency was 8.2%. Domestic sales decreased 0.6%. International sales decreased 13.7%, reflecting operational growth of 2.1% and a negative currency impact of 15.8%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 5.6%, domestic sales increased 7.7% and international sales increased 3.8%.* Earlier today, the Company also announced its Board of Directors has approved the repurchase of up to $10 billion of the company’s common stock.

      Net earnings and diluted earnings per share for the third quarter of 2015 were $3.4 billion and $1.20, respectively. Third quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.4 billion and a charge for after-tax special items of approximately $0.4 billion. Third quarter 2014 net earnings included after-tax intangible amortization expense of approximately $0.3 billion and a net gain for after-tax special items of approximately $0.4 billion. A reconciliation of non-GAAP financial measures is included as an accompanying schedule. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.2 billion and adjusted diluted earnings per share were $1.49, representing decreases of 9.4% and 7.5%, respectively, as compared to the same period in 2014.* On an operational basis, adjusted diluted earnings per share increased 1.2%.*

      “New and core products drove solid underlying growth for Johnson & Johnson in the quarter,” said Alex Gorsky, Chairman and Chief Executive Officer. “Consistent with the plans we’ve laid out for the year, we’re focusing our portfolio and are advancing our innovation agenda to expand our leadership position in key categories while seeking new opportunities for growth. Our dedicated employees are committed to improving healthcare and making a difference in the lives of patients and consumers worldwide.”

      The Company increased its adjusted earnings guidance for full-year 2015 to $6.15 - $6.20 per share. The Company’s guidance excludes the impact of after-tax intangible amortization expense and special items.

      Worldwide Consumer sales of $3.3 billion for the third quarter represented a decrease of 7.7% versus the prior year, consisting of an operational increase of 3.1% and a negative impact from currency of 10.8%. Domestic sales increased 8.9%; international sales decreased 15.7%, which reflected an operational increase of 0.4% and a negative currency impact of 16.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.0%, domestic sales increased 8.9% and international sales increased 1.5%.*

      Positive contributors to Consumer operational results were sales of over-the-counter products including TYLENOL® and MOTRIN® analgesics and ZYRTEC® allergy medications; international feminine protection products; AVEENO® and NEUTROGENA® skin care products; and LISTERINE® oral care products.

      During the quarter, the divestiture of the SPLENDA® low calorie sweetener brand to Heartland Food Products Group was completed. This completes the divestiture of products within the nutritionals business.

      Worldwide Pharmaceutical sales of $7.7 billion for the third quarter represented a decrease of 7.4% versus the prior year with an operational decrease of 0.3% and a negative impact from currency of 7.1%. Domestic sales decreased 4.5%; international sales decreased 11.1%, which reflected an operational increase of 5.5% and a negative currency impact of 16.6%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 10.1%, domestic sales increased 11.5% and international sales increased 8.5%.*

      Worldwide operational sales growth was driven by new products and the strength of core products. New product sales growth was negatively impacted by lower sales of OLYSIO®/SOVRIAD® (simeprevir) due to competitive entrants. Strong growth in new products include INVOKANA®/INVOKAMET® (canagliflozin), for the treatment of adults with type 2 diabetes; IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; XARELTO® (rivaroxaban), an oral anticoagulant; and ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.

      Additional contributors to operational sales growth were SIMPONI®/SIMPONI ARIA® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; CONCERTA® (methylphenidate HCI), for the treatment of attention deficit hyperactivity disorder; and PREZCOBIX®/REZOLSTA® (darunavir/cobicistat) for the treatment of human immunodeficiency virus (HIV-1).

      During the quarter, the U.S. Food and Drug Administration (FDA) granted Priority Review for the Biologic License Application for daratumumab for the treatment of double refractory multiple myeloma. Additionally, the FDA approved EDURANT® (rilpirivine), in combination with other anti-retroviral agents, for treatment-naïve adolescent patients aged 12 to 18 years with human immunodeficiency virus-1 (HIV-1) infection, as well as an update to the SIMPONI ARIA® (golimumab for infusion) label to include improvement in both physical and emotional measures of health when treating moderately to severely active rheumatoid arthritis. In the U.S., a supplemental new drug application was submitted to the FDA for IMBRUVICA® (ibrutinib) for use in treatment-naïve patients with chronic lymphocytic leukemia. In addition, Marketing Authorization Applications were submitted to the European Medicines Agency for paliperidone palmitate once-every-three-months formulation for the treatment of schizophrenia and daratumumab for the treatment of patients with relapsed and refractory multiple myeloma. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted an accelerated assessment of the daratumumab Marketing Authorization Application.

      Worldwide Medical Devices sales of $6.1 billion for the third quarter represented a decrease of 7.3% versus the prior year consisting of an operational increase of 0.9% and a negative currency impact of 8.2%. Domestic sales increased 2.0%; international sales decreased 14.8%, which reflected an operational increase of 0.1% and a negative currency impact of 14.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.3%, domestic sales increased 2.0% and international sales increased 0.8%.*

      Primary contributors to operational growth were sales of ACUVUE® contact lenses in the Vision Care business; endocutters in the Surgical Care business; sales of biosurgicals and international energy products in the Specialty Surgery business; and electrophysiology products in the Cardiovascular Care business.

      In October, subsequent to the third quarter, the Company announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion.

      About Johnson & Johnson
      Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

      * Operational sales growth excluding the net impact of acquisitions, divestitures and hepatitis C sales, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com.

      Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

      Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the Company’s website at www.investor.jnj.com.

      NOTE TO INVESTORS

      This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; market conditions and the possibility that the share repurchase program may be suspended or discontinued; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

      Johnson & Johnson and Subsidiaries



















      Supplementary Sales Data








































      (Unaudited; Dollars in Millions)

      THIRD QUARTER


      NINE MONTHS






      Percent Change






      Percent Change


      2015


      2014


      Total


      Operations


      Currency


      2015


      2014


      Total


      Operations


      Currency

      Sales to customers by




















      segment of business








































      Consumer




















      U.S.

      $ 1,277


      1,173


      8.9

      %

      8.9


      -


      $ 3,991


      3,802


      5.0

      %

      5.0


      -

      International

      2,037


      2,416


      (15.7)


      0.4


      (16.1)


      6,196


      7,088


      (12.6)


      1.9


      (14.5)


      3,314


      3,589


      (7.7)


      3.1


      (10.8)


      10,187


      10,890


      (6.5)


      2.9


      (9.4)





















      Pharmaceutical




















      U.S.

      4,509


      4,723


      (4.5)


      (4.5)


      -


      13,423


      13,076


      2.7


      2.7


      -

      International

      3,185


      3,584


      (11.1)


      5.5


      (16.6)


      9,943


      11,238


      (11.5)


      4.3


      (15.8)


      7,694


      8,307


      (7.4)


      (0.3)


      (7.1)


      23,366


      24,314


      (3.9)


      3.4


      (7.3)





















      Medical Devices




















      U.S.

      3,005


      2,946


      2.0


      2.0


      -


      8,980


      9,300


      (3.4)


      (3.4)


      -

      International

      3,089


      3,625


      (14.8)


      0.1


      (14.9)


      9,730


      11,573


      (15.9)


      (2.4)


      (13.5)


      6,094


      6,571


      (7.3)


      0.9


      (8.2)


      18,710


      20,873


      (10.4)


      (2.9)


      (7.5)





















      U.S.

      8,791


      8,842


      (0.6)


      (0.6)


      -


      26,394


      26,178


      0.8


      0.8


      -

      International

      8,311


      9,625


      (13.7)


      2.1


      (15.8)


      25,869


      29,899


      (13.5)


      1.1


      (14.6)

      Worldwide

      $ 17,102


      18,467


      (7.4)

      %

      0.8


      (8.2)


      $ 52,263


      56,077


      (6.8)

      %

      1.0


      (7.8)





















      Johnson & Johnson and Subsidiaries



















      Supplementary Sales Data








































      (Unaudited; Dollars in Millions)

      THIRD QUARTER


      NINE MONTHS






      Percent Change






      Percent Change


      2015


      2014


      Total


      Operations

      Currency


      2015


      2014


      Total


      Operations

      Currency

      Sales to customers by




















      geographic area








































      U.S.

      $ 8,791


      8,842


      (0.6)

      %

      (0.6)


      -


      $ 26,394


      26,178


      0.8

      %

      0.8


      -





















      Europe

      3,802


      4,446


      (14.5)


      2.7


      (17.2)


      11,993


      14,387


      (16.6)


      1.3


      (17.9)

      Western Hemisphere excluding U.S.

      1,463


      1,820


      (19.6)


      2.7


      (22.3)


      4,603


      5,378


      (14.4)


      2.6


      (17.0)

      Asia-Pacific, Africa

      3,046


      3,359


      (9.3)


      1.2


      (10.5)


      9,273


      10,134


      (8.5)


      0.1


      (8.6)

      International

      8,311


      9,625


      (13.7)


      2.1


      (15.8)


      25,869


      29,899


      (13.5)


      1.1


      (14.6)





















      Worldwide

      $ 17,102


      18,467


      (7.4)

      %

      0.8


      (8.2)


      $ 52,263


      56,077


      (6.8)

      %

      1.0


      (7.8)





















      Johnson & Johnson and Subsidiaries











      Condensed Consolidated Statement of Earnings






















      (Unaudited; in Millions Except Per Share Figures)

      THIRD QUARTER














      2015


      2014


      Percent





      Percent




      Percent


      Increase



      Amount


      to Sales


      Amount


      to Sales


      (Decrease)


      Sales to customers

      $ 17,102


      100.0


      $ 18,467


      100.0


      (7.4)


      Cost of products sold

      5,224


      30.5


      5,399


      29.2


      (3.2)


      Selling, marketing and administrative expenses

      5,081


      29.7


      5,468


      29.6


      (7.1)


      Research and development expense

      2,154


      12.6


      2,023


      11.0


      6.5


      In-process research and development

      10


      0.1


      -


      -




      Interest (income) expense, net

      91


      0.5


      112


      0.6




      Other (income) expense, net

      420


      2.5


      (1,345)


      (7.3)




      Earnings before provision for taxes on income

      4,122


      24.1


      6,810


      36.9


      (39.5)


      Provision for taxes on income

      764


      4.5


      2,061


      11.2


      (62.9)


      Net earnings

      $ 3,358


      19.6


      $ 4,749


      25.7


      (29.3)













      Net earnings per share (Diluted)

      $ 1.20




      $ 1.66




      (27.7)













      Average shares outstanding (Diluted)

      2,807.2




      2,864.3

















      Effective tax rate

      18.5

      %



      30.3

      %
















      Adjusted earnings before provision for taxes and net earnings(1)











      Earnings before provision for taxes on income

      $ 5,212


      30.5


      $ 6,077


      32.9


      (14.2)


      Net earnings

      $ 4,172


      24.4


      $ 4,605


      24.9


      (9.4)


      Net earnings per share (Diluted)

      $ 1.49




      $ 1.61




      (7.5)


      Effective tax rate

      20.0

      %



      24.2

      %
















      (1)See Reconciliation of Non-GAAP Financial Measures.






















      Johnson & Johnson and Subsidiaries










      Condensed Consolidated Statement of Earnings




















      (Unaudited; in Millions Except Per Share Figures)

      NINE MONTHS












      2015


      2014


      Percent




      Percent




      Percent


      Increase


      Amount


      to Sales


      Amount


      to Sales


      (Decrease)

      Sales to customers

      $ 52,263


      100.0


      $ 56,077


      100.0


      (6.8)

      Cost of products sold

      15,863


      30.4


      16,893


      30.1


      (6.1)

      Selling, marketing and administrative expenses

      15,312


      29.3


      16,132


      28.8


      (5.1)

      Research and development expense

      6,182


      11.8


      5,859


      10.5


      5.5

      In-process research and development

      10


      0.0


      22


      0.0



      Interest (income) expense, net

      317


      0.6


      344


      0.6



      Other (income) expense, net

      (859)


      (1.6)


      (1,033)


      (1.8)



      Earnings before provision for taxes on income

      15,438


      29.5


      17,860


      31.8


      (13.6)

      Provision for taxes on income

      3,244


      6.2


      4,058


      7.2


      (20.1)

      Net earnings

      $ 12,194


      23.3


      $ 13,802


      24.6


      (11.7)











      Net earnings per share (Diluted)

      $ 4.33




      $ 4.81




      (10.0)











      Average shares outstanding (Diluted)

      2,817.1




      2,871.2















      Effective tax rate

      21.0

      %



      22.7

      %














      Adjusted earnings before provision for taxes and net earnings(1)










      Earnings before provision for taxes on income

      $ 17,090


      32.7


      $ 18,529


      33.0


      (7.8)

      Net earnings

      $ 13,402


      25.6


      $ 14,431


      25.7


      (7.1)

      Net earnings per share (Diluted)

      $ 4.76




      $ 5.02




      (5.2)

      Effective tax rate

      21.6

      %



      22.1

      %














      (1)See Reconciliation of Non-GAAP Financial Measures.




















      Johnson & Johnson and Subsidiaries














      Reconciliation of Non-GAAP Financial Measures





























      Third Quarter


      % Incr. /



      Nine Months YTD


      % Incr. /


      (Dollars in Millions Except Per Share Data)

      2015


      2014


      (Decr.)



      2015


      2014


      (Decr.)
















      Earnings before provision for taxes on income - as reported

      $ 4,122


      6,810


      (39.5)

      %


      $ 15,438


      17,860


      (13.6)

      %















      Intangible asset amortization expense

      639


      417





      1,269


      1,259


















      Ortho-Clinical Diagnostics divestiture net gain

      -


      (1,948)





      (29)


      (1,948)


















      Litigation expense, net

      409


      285





      141


      561


















      Additional year of Branded Prescription Drug Fee

      -


      220





      -


      220


















      Synthes integration costs

      32


      167





      113


      429


















      In-process research and development

      10


      -





      10


      22


















      DePuy ASRTMHip program

      -


      126





      148


      126


















      Earnings before provision for taxes on income - as adjusted

      $ 5,212


      6,077


      (14.2)

      %


      $ 17,090


      18,529


      (7.8)

      %















      Net Earnings - as reported

      $ 3,358


      4,749


      (29.3)

      %


      $ 12,194


      13,802


      (11.7)

      %















      Intangible asset amortization expense

      437


      313





      893


      938


















      Ortho-Clinical Diagnostics divestiture net gain

      -


      (1,149)





      (24)


      (1,149)


















      Litigation expense, net

      348


      231





      118


      573

      (1)

















      Additional year of Branded Prescription Drug Fee

      -


      220





      -


      220


















      Synthes integration costs

      23


      130





      85


      318


















      In-process research and development

      6


      -





      6


      16


















      DePuy ASRTMHip program

      -


      111





      130


      111


















      Tax benefit associated with Conor Medsystems

      -


      -





      -


      (398)


















      Net Earnings - as adjusted

      $ 4,172


      4,605


      (9.4)

      %


      $ 13,402


      14,431


      (7.1)

      %















      Diluted Net Earnings per share - as reported

      $ 1.20


      1.66


      (27.7)

      %


      $ 4.33


      4.81


      (10.0)

      %















      Intangible asset amortization expense

      0.16


      0.11





      0.32


      0.32


















      Ortho-Clinical Diagnostics divestiture net gain

      -


      (0.40)





      (0.01)


      (0.40)


















      Litigation expense, net

      0.12


      0.08





      0.04


      0.19


















      Additional year of Branded Prescription Drug Fee

      -


      0.08





      -


      0.08


















      Synthes integration costs

      0.01


      0.04





      0.03


      0.11


















      In-process research and development

      -


      -





      -


      0.01


















      DePuy ASRTMHip program

      -


      0.04





      0.05


      0.04


















      Tax benefit associated with Conor Medsystems

      -


      -





      -


      (0.14)


















      Diluted Net Earnings per share - as adjusted

      $ 1.49


      1.61


      (7.5)

      %


      $ 4.76


      5.02


      (5.2)

      %















      Operational Diluted Net Earnings per share - as adjusted*

      $ 1.63


      1.61


      1.2

      %


      $ 5.22


      5.02


      4.0

      %















      *Excludes the effect of translational currency




























      (1)Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction



























      Johnson & Johnson and Subsidiaries









      Reconciliation of Non-GAAP Financial Measure


















      Operational Sales Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales(1)

      THIRD QUARTER 2015 ACTUAL vs. 2014 ACTUAL










      Segments












      Consumer


      Pharmaceutical


      Medical Devices


      Total



      Operational % (2)

      WW As Reported:


      3.1%


      (0.3)%


      0.9%


      0.8%

      U.S.


      8.9%


      (4.5)%


      2.0%


      (0.6)%

      International


      0.4%


      5.5%


      0.1%


      2.1%










      Wound Care / Other









      BENECOL ®


      0.8






      0.1

      U.S.


      0.0






      0.0

      International


      1.0






      0.2










      Diagnostics









      Ortho-Clinical Diagnostics






      0.3


      0.1

      U.S.






      0.0


      0.0

      International






      0.5


      0.2










      Other Neuroscience









      NUCYNTA ®




      0.4




      0.2

      U.S.




      0.6




      0.4

      International




      0.0




      0.0










      All Other Acquisitions and Divestitures


      0.1




      0.1


      0.1

      U.S.


      0.0




      0.0


      0.0

      International


      0.1




      0.2


      0.1










      WW Ops excluding Acquisitions and Divestitures


      4.0%


      0.1%


      1.3%


      1.3%

      U.S.


      8.9%


      (3.9)%


      2.0%


      (0.2)%

      International


      1.5%


      5.5%


      0.8%


      2.6%










      Hepatitis C




      10.0




      4.3

      U.S.




      15.4




      7.9

      International




      3.0




      1.2










      WW Ops excluding Hepatitis C only




      9.7%




      5.1%

      U.S.




      10.9%




      7.3%

      International




      8.5%




      3.3%










      WW Ops excluding Acquisitions, Divestitures and Hepatitis C


      4.0%


      10.1%


      1.3%


      5.6%

      U.S.


      8.9%


      11.5%


      2.0%


      7.7%

      International


      1.5%


      8.5%


      0.8%


      3.8%










      (1)Hepatitis C products include OLYSIO ® /SOVRIAD ® and INCIVO ®









      (2)Operational growth excludes the effect of translational currency









      Johnson & Johnson and Subsidiaries









      Reconciliation of Non-GAAP Financial Measure


















      Operational Sales Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales(1)

      NINE MONTHS 2015 ACTUAL vs. 2014 ACTUAL










      Segments












      Consumer


      Pharmaceutical


      Medical Devices


      Total



      Operational % (2)

      WW As Reported:


      2.9%


      3.4%


      (2.9)%


      1.0%

      U.S.


      5.0%


      2.7%


      (3.4)%


      0.8%

      International


      1.9%


      4.3%


      (2.4)%


      1.1%










      Women’s Health









      K-Y ®


      0.3






      0.1

      U.S.


      0.5






      0.1

      International


      0.2






      0.1










      Wound Care / Other









      BENECOL ®


      0.8






      0.1

      U.S.


      0.0






      0.0

      International


      1.1






      0.3










      Diagnostics









      Ortho-Clinical Diagnostics






      4.2


      1.6

      U.S.






      4.9


      1.8

      International






      3.6


      1.4










      Other Neuroscience









      NUCYNTA ®




      0.3




      0.1

      U.S.




      0.5




      0.3

      International




      0.0




      0.0










      All Other Acquisitions and Divestitures


      (0.1)




      0.1


      0.0

      U.S.


      0.0




      0.0


      0.0

      International


      (0.2)




      0.1


      0.0










      WW Ops excluding Acquisitions and Divestitures


      3.9%


      3.7%


      1.4%


      2.9%

      U.S.


      5.5%


      3.2%


      1.5%


      3.0%

      International


      3.0%


      4.3%


      1.3%


      2.9%










      Hepatitis C




      7.3




      3.0

      U.S.




      13.9




      6.5

      International




      0.2




      0.0










      WW Ops excluding Hepatitis C only




      10.7%




      4.0%

      U.S.




      16.6%




      7.3%

      International




      4.5%




      1.1%










      WW Ops excluding Acquisitions, Divestitures and Hepatitis C


      3.9%


      11.0%


      1.4%


      5.9%

      U.S.


      5.5%


      17.1%


      1.5%


      9.5%

      International


      3.0%


      4.5%


      1.3%


      2.9%










      (1)Hepatitis C products include OLYSIO ® /SOVRIAD ® and INCIVO ® (2)Operational growth excludes the effect of translational currency



























      REPORTED SALES vs. PRIOR PERIOD ($MM)


      THIRD QUARTER


      NINE MONTHS







      % Change







      % Change



      2015


      2014

      Reported

      Operational (1)

      Currency



      2015


      2014

      Reported

      Operational (1)

      Currency

      CONSUMER SEGMENT (2)
















      BABY CARE
















      US


      $ 103


      102

      1.0%

      1.0%

      -



      $ 318


      311

      2.3%

      2.3%

      -

      Intl


      403


      461

      -12.6%

      2.1%

      -14.7%



      1,242


      1,404

      -11.5%

      0.1%

      -11.6%

      WW


      506


      563

      -10.1%

      2.0%

      -12.1%



      1,560


      1,715

      -9.0%

      0.5%

      -9.5%

      ORAL CARE
















      US


      154


      148

      4.1%

      4.1%

      -



      459


      450

      2.0%

      2.0%

      -

      Intl


      224


      261

      -14.2%

      3.2%

      -17.4%



      713


      783

      -8.9%

      5.7%

      -14.6%

      WW


      378


      409

      -7.6%

      3.5%

      -11.1%



      1,172


      1,233

      -4.9%

      4.4%

      -9.3%

      OTC
















      US


      383


      313

      22.4%

      22.4%

      -



      1,154


      995

      16.0%

      16.0%

      -

      Intl


      580


      706

      -17.8%

      -0.7%

      -17.1%



      1,776


      2,038

      -12.9%

      4.1%

      -17.0%

      WW


      963


      1,019

      -5.5%

      6.3%

      -11.8%



      2,930


      3,033

      -3.4%

      8.1%

      -11.5%

      SKIN CARE
















      US


      435


      400

      8.8%

      8.8%

      -



      1,418


      1,363

      4.0%

      4.0%

      -

      Intl


      428


      520

      -17.7%

      -2.3%

      -15.4%



      1,242


      1,439

      -13.7%

      0.1%

      -13.8%

      WW


      863


      920

      -6.2%

      2.5%

      -8.7%



      2,660


      2,802

      -5.1%

      2.0%

      -7.1%

      WOMEN’S HEALTH
















      US


      6


      8

      -25.0%

      -25.0%

      -



      19


      43

      -55.8%

      -55.8%

      -

      Intl


      304


      317

      -4.1%

      14.2%

      -18.3%



      898


      951

      -5.6%

      10.4%

      -16.0%

      WW


      310


      325

      -4.6%

      13.3%

      -17.9%



      917


      994

      -7.7%

      7.6%

      -15.3%

      WOUND CARE / OTHER
















      US


      196


      202

      -3.0%

      -3.0%

      -



      623


      640

      -2.7%

      -2.7%

      -

      Intl


      98


      151

      -35.1%

      -23.9%

      -11.2%



      325


      473

      -31.3%

      -20.8%

      -10.5%

      WW


      294


      353

      -16.7%

      -11.9%

      -4.8%



      948


      1,113

      -14.8%

      -10.3%

      -4.5%

















      TOTAL CONSUMER
















      US


      1,277


      1,173

      8.9%

      8.9%

      -



      3,991


      3,802

      5.0%

      5.0%

      -

      Intl


      2,037


      2,416

      -15.7%

      0.4%

      -16.1%



      6,196


      7,088

      -12.6%

      1.9%

      -14.5%

      WW


      $ 3,314


      3,589

      -7.7%

      3.1%

      -10.8%



      $ 10,187


      10,890

      -6.5%

      2.9%

      -9.4%


















































      REPORTED SALES vs. PRIOR PERIOD ($MM)


      THIRD QUARTER


      NINE MONTHS






      % Change






      % Change



      2015


      2014

      Reported

      Operational (1)

      Currency



      2015


      2014

      Reported

      Operational (1)

      Currency

      PHARMACEUTICAL SEGMENT (2) (3)
















      IMMUNOLOGY
















      US


      $ 1,910


      1,895

      0.8%

      0.8%

      -



      $ 5,541


      5,295

      4.6%

      4.6%

      -

      Intl


      704


      746

      -5.6%

      13.5%

      -19.1%



      2,090


      2,320

      -9.9%

      6.6%

      -16.5%

      WW


      2,614


      2,641

      -1.0%

      4.4%

      -5.4%



      7,631


      7,615

      0.2%

      5.2%

      -5.0%

      REMICADE
















      US


      1,117


      1,085

      2.9%

      2.9%

      -



      3,260


      3,103

      5.1%

      5.1%

      -

      US Exports (4)


      180


      310

      -41.9%

      -41.9%

      -



      602


      834

      -27.8%

      -27.8%

      -

      Intl


      316


      387

      -18.3%

      -1.6%

      -16.7%



      1,019


      1,259

      -19.1%

      -5.0%

      -14.1%

      WW


      1,613


      1,782

      -9.5%

      -5.9%

      -3.6%



      4,881


      5,196

      -6.1%

      -2.7%

      -3.4%

      SIMPONI / SIMPONI ARIA
















      US


      199


      144

      38.2%

      38.2%

      -



      526


      380

      38.4%

      38.4%

      -

      Intl


      181


      156

      16.0%

      40.7%

      -24.7%



      462


      461

      0.2%

      20.1%

      -19.9%

      WW


      380


      300

      26.7%

      39.6%

      -12.9%



      988


      841

      17.5%

      28.4%

      -10.9%

      STELARA
















      US


      414


      356

      16.3%

      16.3%

      -



      1,153


      978

      17.9%

      17.9%

      -

      Intl


      199


      187

      6.4%

      26.3%

      -19.9%



      579


      549

      5.5%

      25.2%

      -19.7%

      WW


      613


      543

      12.9%

      19.7%

      -6.8%



      1,732


      1,527

      13.4%

      20.5%

      -7.1%

      OTHER IMMUNOLOGY
















      US


      -


      -

      -

      -

      -



      -


      -

      -

      -

      -

      Intl


      8


      16

      -50.0%

      -37.2%

      -12.8%



      30


      51

      -41.2%

      -31.4%

      -9.8%

      WW


      8


      16

      -50.0%

      -37.2%

      -12.8%



      30


      51

      -41.2%

      -31.4%

      -9.8%

      INFECTIOUS DISEASES
















      US


      379


      967

      -60.8%

      -60.8%

      -



      1,172


      2,548

      -54.0%

      -54.0%

      -

      Intl


      469


      594

      -21.0%

      -5.7%

      -15.3%



      1,683


      1,975

      -14.8%

      2.4%

      -17.2%

      WW


      848


      1,561

      -45.7%

      -39.9%

      -5.8%



      2,855


      4,523

      -36.9%

      -29.4%

      -7.5%

      EDURANT
















      US


      11


      7

      57.1%

      57.1%

      -



      29


      18

      61.1%

      61.1%

      -

      Intl


      100


      95

      5.3%

      25.4%

      -20.1%



      274


      257

      6.6%

      29.1%

      -22.5%

      WW


      111


      102

      8.8%

      27.6%

      -18.8%



      303


      275

      10.2%

      31.3%

      -21.1%

      OLYSIO / SOVRIAD
















      US


      26


      671

      -96.1%

      -96.1%

      -



      174


      1,687

      -89.7%

      -89.7%

      -

      Intl


      53


      125

      -57.6%

      -49.5%

      -8.1%



      403


      294

      37.1%

      66.0%

      -28.9%

      WW


      79


      796

      -90.1%

      -88.8%

      -1.3%



      577


      1,981

      -70.9%

      -66.6%

      -4.3%

      PREZISTA / PREZCOBIX / REZOLSTA
















      US


      285


      234

      21.8%

      21.8%

      -



      777


      687

      13.1%

      13.1%

      -

      Intl


      183


      212

      -13.7%

      4.3%

      -18.0%



      566


      696

      -18.7%

      -2.0%

      -16.7%

      WW


      468


      446

      4.9%

      13.4%

      -8.5%



      1,343


      1,383

      -2.9%

      5.5%

      -8.4%

      OTHER INFECTIOUS DISEASES
















      US


      57


      55

      3.6%

      3.6%

      -



      192


      156

      23.1%

      23.1%

      -

      Intl


      133


      162

      -17.9%

      -3.4%

      -14.5%



      440


      728

      -39.6%

      -28.6%

      -11.0%

      WW


      190


      217

      -12.4%

      -1.6%

      -10.8%



      632


      884

      -28.5%

      -19.4%

      -9.1%

















      See footnotes at end of schedule

















      REPORTED SALES vs. PRIOR PERIOD ($MM)


      THIRD QUARTER


      NINE MONTHS






      % Change






      % Change



      2015


      2014

      Reported

      Operational (1)

      Currency



      2015


      2014

      Reported

      Operational (1)

      Currency

















      NEUROSCIENCE
















      US


      655


      606

      8.1%

      8.1%

      -



      2,098


      1,807

      16.1%

      16.1%

      -

      Intl


      821


      965

      -14.9%

      0.4%

      -15.3%



      2,560


      3,029

      -15.5%

      -1.1%

      -14.4%

      WW


      1,476


      1,571

      -6.0%

      3.4%

      -9.4%



      4,658


      4,836

      -3.7%

      5.3%

      -9.0%

      CONCERTA / METHYLPHENIDATE
















      US


      89


      34

      *

      *

      -



      317


      97

      *

      *

      -

      Intl


      89


      101

      -11.9%

      3.9%

      -15.8%



      291


      333

      -12.6%

      0.9%

      -13.5%

      WW


      178


      135

      31.9%

      43.7%

      -11.8%



      608


      430

      41.4%

      51.9%

      -10.5%

      INVEGA / PALIPERIDONE
















      US


      82


      89

      -7.9%

      -7.9%

      -



      281


      264

      6.4%

      6.4%

      -

      Intl


      57


      67

      -14.9%

      -0.4%

      -14.5%



      179


      215

      -16.7%

      -2.1%

      -14.6%

      WW


      139


      156

      -10.9%

      -4.7%

      -6.2%



      460


      479

      -4.0%

      2.6%

      -6.6%

      INVEGA SUSTENNA / XEPLION / INVEGA TRINZA
















      US


      277


      215

      28.8%

      28.8%

      -



      758


      599

      26.5%

      26.5%

      -

      Intl


      182


      188

      -3.2%

      14.9%

      -18.1%



      548


      571

      -4.0%

      14.0%

      -18.0%

      WW


      459


      403

      13.9%

      22.4%

      -8.5%



      1,306


      1,170

      11.6%

      20.4%

      -8.8%

      RISPERDAL CONSTA
















      US


      103


      107

      -3.7%

      -3.7%

      -



      306


      323

      -5.3%

      -5.3%

      -

      Intl


      132


      177

      -25.4%

      -10.6%

      -14.8%



      430


      573

      -25.0%

      -10.2%

      -14.8%

      WW


      235


      284

      -17.3%

      -8.1%

      -9.2%



      736


      896

      -17.9%

      -8.4%

      -9.5%

      OTHER NEUROSCIENCE
















      US


      104


      161

      -35.4%

      -35.4%

      -



      436


      524

      -16.8%

      -16.8%

      -

      Intl


      361


      432

      -16.4%

      -2.0%

      -14.4%



      1,112


      1,337

      -16.8%

      -3.9%

      -12.9%

      WW


      465


      593

      -21.6%

      -11.2%

      -10.4%



      1,548


      1,861

      -16.8%

      -7.5%

      -9.3%

      ONCOLOGY
















      US


      394


      305

      29.2%

      29.2%

      -



      1,090


      823

      32.4%

      32.4%

      -

      Intl


      776


      807

      -3.8%

      14.3%

      -18.1%



      2,332


      2,422

      -3.7%

      14.2%

      -17.9%

      WW


      1,170


      1,112

      5.2%

      18.4%

      -13.2%



      3,422


      3,245

      5.5%

      18.9%

      -13.4%

      IMBRUVICA
















      US


      98


      42

      *

      *

      -



      253


      81

      *

      *

      -

      Intl


      86


      14

      *

      *

      **



      201


      27

      *

      *

      **

      WW


      184


      56

      *

      *

      **



      454


      108

      *

      *

      **

      VELCADE
















      US


      -


      -

      -

      -

      -



      -


      -

      -

      -

      -

      Intl


      329


      389

      -15.4%

      0.1%

      -15.5%



      1,012


      1,200

      -15.7%

      -1.0%

      -14.7%

      WW


      329


      389

      -15.4%

      0.1%

      -15.5%



      1,012


      1,200

      -15.7%

      -1.0%

      -14.7%

      ZYTIGA
















      US


      276


      252

      9.5%

      9.5%

      -



      784


      716

      9.5%

      9.5%

      -

      Intl


      272


      316

      -13.9%

      3.4%

      -17.3%



      866


      926

      -6.5%

      12.2%

      -18.7%

      WW


      548


      568

      -3.5%

      6.1%

      -9.6%



      1,650


      1,642

      0.5%

      11.0%

      -10.5%

      OTHER ONCOLOGY
















      US


      20


      11

      81.8%

      81.8%

      -



      53


      26

      *

      *

      -

      Intl


      89


      88

      1.1%

      19.3%

      -18.2%



      253


      269

      -5.9%

      11.5%

      -17.4%

      WW


      109


      99

      10.1%

      26.2%

      -16.1%



      306


      295

      3.7%

      19.5%

      -15.8%

      CARDIOVASCULAR / METABOLISM / OTHER (5)
















      US


      1,171


      950

      23.3%

      23.3%

      -



      3,522


      2,603

      35.3%

      35.3%

      -

      Intl


      415


      472

      -12.1%

      1.8%

      -13.9%



      1,278


      1,492

      -14.3%

      -1.9%

      -12.4%

      WW


      1,586


      1,422

      11.5%

      16.1%

      -4.6%



      4,800


      4,095

      17.2%

      21.7%

      -4.5%

      XARELTO
















      US


      461


      414

      11.4%

      11.4%

      -



      1,374


      1,094

      25.6%

      25.6%

      -

      Intl


      -


      -

      -

      -

      -



      -


      -

      -

      -

      -

      WW


      461


      414

      11.4%

      11.4%

      -



      1,374


      1,094

      25.6%

      25.6%

      -

      INVOKANA / INVOKAMET
















      US


      322


      169

      90.5%

      90.5%

      -



      890


      376

      *

      *

      -

      Intl


      18


      5

      *

      *

      **



      46


      9

      *

      *

      **

      WW


      340


      174

      95.4%

      97.3%

      -1.9%



      936


      385

      *

      *

      **

      PROCRIT / EPREX
















      US


      177


      184

      -3.8%

      -3.8%

      -



      519


      538

      -3.5%

      -3.5%

      -

      Intl


      86


      123

      -30.1%

      -17.1%

      -13.0%



      289


      398

      -27.4%

      -14.4%

      -13.0%

      WW


      263


      307

      -14.3%

      -9.1%

      -5.2%



      808


      936

      -13.7%

      -8.2%

      -5.5%

      OTHER
















      US


      211


      183

      15.3%

      15.3%

      -



      739


      595

      24.2%

      24.2%

      -

      Intl


      311


      344

      -9.6%

      3.8%

      -13.4%



      943


      1,085

      -13.1%

      -1.5%

      -11.6%

      WW


      522


      527

      -0.9%

      7.9%

      -8.8%



      1,682


      1,680

      0.1%

      7.6%

      -7.5%

















      TOTAL PHARMACEUTICAL
















      US


      4,509


      4,723

      -4.5%

      -4.5%

      -



      13,423


      13,076

      2.7%

      2.7%

      -

      Intl


      3,185


      3,584

      -11.1%

      5.5%

      -16.6%



      9,943


      11,238

      -11.5%

      4.3%

      -15.8%

      WW


      $ 7,694


      8,307

      -7.4%

      -0.3%

      -7.1%



      $ 23,366


      24,314

      -3.9%

      3.4%

      -7.3%

















































      See footnotes at end of schedule

















































      REPORTED SALES vs. PRIOR PERIOD ($MM)


      THIRD QUARTER


      NINE MONTHS







      % Change







      % Change



      2015


      2014

      Reported

      Operational (1)

      Currency



      2015


      2014

      Reported

      Operational (1)

      Currency

      MEDICAL DEVICES (2)
















      CARDIOVASCULAR CARE
















      US


      $ 239


      221

      8.1%

      8.1%

      -



      $ 702


      640

      9.7%

      9.7%

      -

      Intl


      285


      321

      -11.2%

      3.1%

      -14.3%



      895


      1,010

      -11.4%

      2.7%

      -14.1%

      WW


      524


      542

      -3.3%

      5.2%

      -8.5%



      1,597


      1,650

      -3.2%

      5.4%

      -8.6%

      DIABETES CARE
















      US


      205


      244

      -16.0%

      -16.0%

      -



      631


      658

      -4.1%

      -4.1%

      -

      Intl


      265


      314

      -15.6%

      1.1%

      -16.7%



      817


      970

      -15.8%

      0.1%

      -15.9%

      WW


      470


      558

      -15.8%

      -6.4%

      -9.4%



      1,448


      1,628

      -11.1%

      -1.6%

      -9.5%

      DIAGNOSTICS (6)
















      US


      -


      -

      -

      -

      -



      -


      456

      **

      **

      -

      Intl


      16


      44

      -63.6%

      -39.8%

      -23.8%



      62


      492

      -87.4%

      -82.7%

      -4.7%

      WW


      16


      44

      -63.6%

      -39.8%

      -23.8%



      62


      948

      -93.5%

      -91.0%

      -2.5%

      ORTHOPAEDICS
















      US


      1,312


      1,272

      3.1%

      3.1%

      -



      3,942


      3,858

      2.2%

      2.2%

      -

      Intl


      869


      1,072

      -18.9%

      -5.0%

      -13.9%



      2,897


      3,376

      -14.2%

      -0.8%

      -13.4%

      WW


      2,181


      2,344

      -7.0%

      -0.7%

      -6.3%



      6,839


      7,234

      -5.5%

      0.8%

      -6.3%

      SPECIALTY SURGERY / OTHER
















      US


      420


      413

      1.7%

      1.7%

      -



      1,275


      1,254

      1.7%

      1.7%

      -

      Intl


      401


      445

      -9.9%

      5.1%

      -15.0%



      1,258


      1,383

      -9.0%

      4.8%

      -13.8%

      WW


      821


      858

      -4.3%

      3.5%

      -7.8%



      2,533


      2,637

      -3.9%

      3.3%

      -7.2%

      SURGICAL CARE
















      US


      567


      564

      0.5%

      0.5%

      -



      1,672


      1,654

      1.1%

      1.1%

      -

      Intl


      832


      957

      -13.1%

      1.1%

      -14.2%



      2,599


      2,950

      -11.9%

      1.4%

      -13.3%

      WW


      1,399


      1,521

      -8.0%

      0.9%

      -8.9%



      4,271


      4,604

      -7.2%

      1.3%

      -8.5%

      VISION CARE
















      US


      262


      232

      12.9%

      12.9%

      -



      758


      780

      -2.8%

      -2.8%

      -

      Intl


      421


      472

      -10.8%

      5.8%

      -16.6%



      1,202


      1,392

      -13.6%

      1.4%

      -15.0%

      WW


      683


      704

      -3.0%

      8.1%

      -11.1%



      1,960


      2,172

      -9.8%

      -0.2%

      -9.6%

















      TOTAL MEDICAL DEVICES
















      US


      3,005


      2,946

      2.0%

      2.0%

      -



      8,980


      9,300

      -3.4%

      -3.4%

      -

      Intl


      3,089


      3,625

      -14.8%

      0.1%

      -14.9%



      9,730


      11,573

      -15.9%

      -2.4%

      -13.5%

      WW


      $ 6,094


      6,571

      -7.3%

      0.9%

      -8.2%



      $ 18,710


      20,873

      -10.4%

      -2.9%

      -7.5%

































      * Percentage greater than 100%
















      ** Not meaningful
















      (1) Operational growth excludes the effect of translational currency













      (2) Unaudited
















      (3) Prior year amounts have been reclassified to conform to current year product disclosure










      (4) Reported as U.S. sales
















      (5) Previously referred to as Other
















      (6) Reflects Diagnostics divestiture June 30, 2014














































      SOURCE Johnson & Johnson

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.